Approximately 30% of non-small cell lung cancer (NSCLC) tumors harbor a mutation in the epidermal growth factor receptor (EGFR) gene, with geographical variation in rates reported to be highest in Asia (38%) and lowest in Europe (14%) [1]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.